5 Responses to “Is it time to stop surveying Barrett esophagus?”
M. Brian Fennerty, MD
Founding Editor
NEJM Journal Watch Gastroenterology
Learn more about Gut Check on Gastroenterology.
From NEJM: Recently in Gastroenterology- Operative versus Nonoperative Management for Appendicitis July 2, 2026This feature about treatment of appendicitis offers a case vignette accompanied by two essays, one recommending operative management and the other supporting a nonoperative approach.
- Artificial Intelligence and Detection of Hirschsprung Disease July 2, 2026This artificial intelligence–derived and validated machine-learning system appeared to predict the risk of Hirschsprung disease with the use of genetic and demographic data from participants in China.
- A Major Step toward a Cure for Hepatitis B Infection June 25, 2026The current treatment of chronic hepatitis B infection includes nucleoside or nucleotide analogue (NA) therapy and pegylated interferon. Both of these treatments are effective in suppressing hepatitis B virus (HBV) replication and in reducing the risk of cirrhosis and hepatocellular carcinoma.1 However, these treatments do not eradicate HBV,...
- Prevention and Treatment of Peanut Allergy June 25, 2026Peanuts should be introduced at 4 to 6 months of age in infants at high risk for allergy and at approximately 6 months of age in other infants. For infants with peanut allergy, early immunotherapy is safer and more effective.
- Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection June 25, 2026In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo.
- Operative versus Nonoperative Management for Appendicitis July 2, 2026
I’m not a doctor but the thought of money being detrimental to the screening for BE is scary….On the other hand, I’m a business owner and understand how business runs!! Mmmmm…interesting discussion. I’ll keep checking in to see how it unfolds.
I, too, am not a doctor, but I have Barrett esophagus. I’ve been having periodic screenings at my gastroenterologist’s suggestion because my father had esophageal cancer. The incidence of cancer in a population may be low, but it needs to be a decision the doctor and patient make together, depending on the patient’s circumstances and medical history.
I think this issue is exemplary of how different points of view can be conflicting. On one side the societal perspective suggests continuing monitoring of BE isn’t worthwhile, the balance being between effectiveness and cost. On the other side the individual perspective affirms: “a low, or very low risk isn’t no risk at all therefore I’d like to continue monitoring even if it produces little good unless the balance between harm and good is decidely shifted”. The sound rationale against PSA screening conjugates the societal perspective: “it is useless” with the individual perspective: “it can do more harm than good”. Until harm from BE monitoring is documented a clearcut position on this issue will be difficult at a clinical level although I feel there is now adequate evidence to reconsidere BE monitoring in the coverage of Health Plans
We should stop surveying Barrett esophagus，but it is not now，why？TO some patient，it saves money，to others，lt means the lost of the chance of early detection for cancer。so，at least by now，we should continue it，but not to all patient。Who should？maybe
patient with high risks into tumor？Now，who is patient with high risks into tumor？it is the key，if we get the key，we solve the problem。
An asymptomatic person does not need a workup but should be endoscoped if a family history of BE exists. A person with esophagitis symptoms would likely be endoscoped; if dysplastic BE is found, that person needs
followup and possible therapy. If non-dysplastic BE is found, we await the next controlled study to determine the appropriate next step. Simple.